As you can read from the below listed article Cyberonics just posted record earnings. What they have not addressed is the Depression Study Subjects who are benefiting from the therapy and to obtain replacement devices and those seeking removal and/or care cannot obtain Medicare/Medicaid or health insurance coverage and reimbursement What they have failed to discuss is their reneging on their “Lifetime Reimbursement Guarantee for All TRD IDE Study Patients and $15 Million TRD Indigent Care Program".
Please read and join our petition to better understand the problems faced by all volunteer medical study subjects. At the same time please consider sharing this petition amongst your family and friends as well as Facebook, Twitter and any blogs you may participate on.
Caution: Do not volunteer for any medical research until you read this petition
Warmly,
Herb
vnsdepression@gmail.com
Cyberonics Reports Record Quarter And Annual Results And Provides Fiscal 2014 Guidance
June 5, 2013 7:00 AM ET
Fiscal 2013 Net Sales of $254 million, a 16% Increase Record Income from Operations
HOUSTON, June 5, 2013 /PRNewswire/ -- Cyberonics, Inc. CYBX today announced results for the fourth quarter and fiscal year ended April 26, 2013.
Annual highlights
Operating results for fiscal 2013 compared with fiscal 2012, and other achievements, include:
Operating results for the fourth quarter of fiscal 2013 compared to the fourth quarter of fiscal 2012 include:
Results and fiscal 2014 objectives
"For the fifth year in a row, the company achieved record net sales and record operating margins," commented Dan Moore, Cyberonics' President and Chief Executive Officer. "Since fiscal 2008, net sales have more than doubled from $121 million to more than $254 million, while operating income has grown from a loss of $8 million in fiscal 2008 to a gain of $78 million in the most recent fiscal year. Epilepsy sales growth has averaged 17% over a period of challenging economic times. We are proud of the entire Cyberonics team for this consistent performance. The results demonstrate the underlying strength of our worldwide epilepsy business, as well as the ongoing opportunity within the underserved population of people suffering from epilepsy.
"In fiscal 2014, we will begin the transition from the handheld programming device to a more functional tablet-based programming device. This new programming platform will have more capabilities, including those necessary to adjust dosing parameters for both the AspireSR™ (seizure response) and the Relay™ (wireless) generators, but comes at a higher cost to the company than the previous handheld device.
"Our product development teams are working hard to bring our key projects to commercialization. In fiscal 2014, we expect to submit both our AspireSR and ProGuardian™ products for regulatory approval in Europe, as well as advance the Relay generator through product development," concluded Mr. Moore.
Depression update
As previously announced, the Centers for Medicare and Medicaid Services declined the company's request to reconsider the 2007 Non-Coverage Determination for the treatment-resistant depression indication. The company plans to work with other interested parties to continue to pursue access to this important therapeutic option for patients who could benefit from VNS Therapy®, including carefully evaluating all options for obtaining a review of this decision.
Stock repurchase update
During the recently completed quarter, Cyberonics repurchased 270,000 shares on the open market, completing the previously authorized program, and leaving 945,000 shares available to be repurchased under the current program.
Fiscal 2014 guidance
Cyberonics is providing guidance for fiscal 2014 as follows:
Net sales are expected to be in the range of $279 million to $283 million. The assumptions in setting this range include:
Net income for fiscal 2014 is expected to be in the range from $53 million to $56 million.
The company expects that diluted earnings per share (EPS +0.29%) will be in the range from $1.93 to $2.01.
Additional details will be provided during today's conference call and in an investor presentation summarizing the company's fourth quarter and fiscal year 2013 results, which is available in the investor relations section of Cyberonics' corporate website at http://www.cyberonics.com.
Use of non-GAAP financial measures
In this press announcement, management has disclosed financial measurements that present financial information not in accordance with Generally Accepted Accounting Principles (GAAP). These measurements are not a substitute for GAAP measurements, although company management uses these measurements as aids in monitoring the company's ongoing financial performance from quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies. Adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measure the net income and income per share of the company excluding for fiscal 2013 the impairment of investment and the gain on warrant liability, which management considers relevant for an investor's understanding of the company's financial performance. Adjusted non-GAAP income from operations, adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measure the income from operations, net income and income per share of the company excluding for fiscal 2012 the impairment of intangible and the impact of the product withdrawal, which management considers relevant for an investor's understanding of the company's financial performance. Management uses and presents adjusted non-GAAP income from operations, adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measures because management believes they facilitate an understanding of the financial impact of such unusual items on the company's short- and long-term financial trends. Management also uses such adjusted non-GAAP items to forecast and to evaluate the operational performance of the company, as well as to compare results of current periods to prior periods on a consistent basis. Adjusted earnings before interest, tax, depreciation and amortization ("EBITDA") measures the income from operations of the company and excludes the aforementioned items, as well as non-cash equity compensation and other income (expense) items.
Non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
Please refer to the attached reconciliations between GAAP and non-GAAP financial measures.
Fourth quarter and fiscal year 2013 results webcast and conference call instructions
Cyberonics will host a conference call today, June 5, 2013, beginning at 8:00 a.m. Central Time (9:00 a.m. Eastern Time) to review its results of operations for the fiscal year 2013 fourth quarter, followed by a question and answer session.
The conference call will be available to interested parties through a live audio webcast in the Investor Relations section of Cyberonics' corporate website at http://www.cyberonics.com. To listen to the conference call live by telephone, dial 877-638-4557 (if dialing from within the U.S.) or 914-495-8522 (if dialing from outside the U.S.). The conference ID is 28969045.
Within 24 hours of the webcast, a replay will be available under the "Events & Presentations" section of the Investor Relations portion of the Cyberonics website, where it will be archived and accessible for approximately 12 months.
About Cyberonics, Inc. and the VNS Therapy System
Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.
Safe harbor statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words. Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning introducing a new tablet-based programming device, filing regulatory submissions in Europe for the AspireSR, and the ProGuardian product by the end of fiscal 2014, as well as advancing the Relay generator, and obtaining a review of CMS's 2007 Non-Coverage Determination, obtaining reimbursement for the treatment-resistant depression indication, and financial guidance for fiscal 2014. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our products; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of new products, including VNS Therapy for the treatment of other indications; satisfactory completion of the post-market registry required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new products and indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 27, 2012, our Quarterly Report on Form 10-Q for the fiscal quarter ended July 27, 2012, our Quarterly Report on Form 10Q for the fiscal quarter ended October 26, 2012, and our Quarterly Report on Form 10Q for the fiscal quarter ended January 25, 2013.
Contact information
Greg Browne, CFOCyberonics, Inc.100 Cyberonics Blvd.Houston, TX 77058Main: (281) 228-7262Fax: (281) 218-9332ir@cyberonics.com
Annual highlights
Operating results for fiscal 2013 compared with fiscal 2012, and other achievements, include:
- Record net sales of $254 million, an increase of 16% from $219 million;
- U.S. epilepsy net sales increased by 15%;
- International net sales increased by 27% on a constant currency basis;
- Record income from operations of $78 million, an increase of 25% from an adjusted non-GAAP income from operations of $63 million;
- Adjusted non-GAAP income per diluted share of $1.74, an increase of 32% from an adjusted non-GAAP income per diluted share of $1.32;
- Adjusted EBITDA of $95 million, an increase of 21%;
- Share repurchases of $33 million; and
- Cash and short term investments increased by $39 million over the fiscal year.
Operating results for the fourth quarter of fiscal 2013 compared to the fourth quarter of fiscal 2012 include:
- Record net sales of $68.3 million, an increase of 19% from $57.6 million;
- Record worldwide unit sales of 3,436, an increase of 15%;
- Record U.S. net sales of $56.1 million, an increase of 17%;
- Record international unit sales of 1,002, an increase of 27%;
- Income from operations increased by 14%; and
- Adjusted non-GAAP income per diluted share of $0.46 compared with $0.38, an increase of 21%.
Results and fiscal 2014 objectives
"For the fifth year in a row, the company achieved record net sales and record operating margins," commented Dan Moore, Cyberonics' President and Chief Executive Officer. "Since fiscal 2008, net sales have more than doubled from $121 million to more than $254 million, while operating income has grown from a loss of $8 million in fiscal 2008 to a gain of $78 million in the most recent fiscal year. Epilepsy sales growth has averaged 17% over a period of challenging economic times. We are proud of the entire Cyberonics team for this consistent performance. The results demonstrate the underlying strength of our worldwide epilepsy business, as well as the ongoing opportunity within the underserved population of people suffering from epilepsy.
"In fiscal 2014, we will begin the transition from the handheld programming device to a more functional tablet-based programming device. This new programming platform will have more capabilities, including those necessary to adjust dosing parameters for both the AspireSR™ (seizure response) and the Relay™ (wireless) generators, but comes at a higher cost to the company than the previous handheld device.
"Our product development teams are working hard to bring our key projects to commercialization. In fiscal 2014, we expect to submit both our AspireSR and ProGuardian™ products for regulatory approval in Europe, as well as advance the Relay generator through product development," concluded Mr. Moore.
Depression update
As previously announced, the Centers for Medicare and Medicaid Services declined the company's request to reconsider the 2007 Non-Coverage Determination for the treatment-resistant depression indication. The company plans to work with other interested parties to continue to pursue access to this important therapeutic option for patients who could benefit from VNS Therapy®, including carefully evaluating all options for obtaining a review of this decision.
Stock repurchase update
During the recently completed quarter, Cyberonics repurchased 270,000 shares on the open market, completing the previously authorized program, and leaving 945,000 shares available to be repurchased under the current program.
Fiscal 2014 guidance
Cyberonics is providing guidance for fiscal 2014 as follows:
Net sales are expected to be in the range of $279 million to $283 million. The assumptions in setting this range include:
- Worldwide unit growth of approximately 10%;
- Mid-to-high single-digit growth in U.S. new patient implants;
- Mid-single-digit growth in U.S. replacement implants;
- Continued European growth, although at a slower rate; and
- Euro/Dollar exchange rate of $1.30.
- a full year of the medical device tax; and
- declining gross profit over the year as costs relating to the Costa Rican facility and the introduction of our new tablet programmer increase through the year.
Net income for fiscal 2014 is expected to be in the range from $53 million to $56 million.
The company expects that diluted earnings per share (EPS +0.29%) will be in the range from $1.93 to $2.01.
Additional details will be provided during today's conference call and in an investor presentation summarizing the company's fourth quarter and fiscal year 2013 results, which is available in the investor relations section of Cyberonics' corporate website at http://www.cyberonics.com.
Use of non-GAAP financial measures
In this press announcement, management has disclosed financial measurements that present financial information not in accordance with Generally Accepted Accounting Principles (GAAP). These measurements are not a substitute for GAAP measurements, although company management uses these measurements as aids in monitoring the company's ongoing financial performance from quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies. Adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measure the net income and income per share of the company excluding for fiscal 2013 the impairment of investment and the gain on warrant liability, which management considers relevant for an investor's understanding of the company's financial performance. Adjusted non-GAAP income from operations, adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measure the income from operations, net income and income per share of the company excluding for fiscal 2012 the impairment of intangible and the impact of the product withdrawal, which management considers relevant for an investor's understanding of the company's financial performance. Management uses and presents adjusted non-GAAP income from operations, adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measures because management believes they facilitate an understanding of the financial impact of such unusual items on the company's short- and long-term financial trends. Management also uses such adjusted non-GAAP items to forecast and to evaluate the operational performance of the company, as well as to compare results of current periods to prior periods on a consistent basis. Adjusted earnings before interest, tax, depreciation and amortization ("EBITDA") measures the income from operations of the company and excludes the aforementioned items, as well as non-cash equity compensation and other income (expense) items.
Non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
Please refer to the attached reconciliations between GAAP and non-GAAP financial measures.
Fourth quarter and fiscal year 2013 results webcast and conference call instructions
Cyberonics will host a conference call today, June 5, 2013, beginning at 8:00 a.m. Central Time (9:00 a.m. Eastern Time) to review its results of operations for the fiscal year 2013 fourth quarter, followed by a question and answer session.
The conference call will be available to interested parties through a live audio webcast in the Investor Relations section of Cyberonics' corporate website at http://www.cyberonics.com. To listen to the conference call live by telephone, dial 877-638-4557 (if dialing from within the U.S.) or 914-495-8522 (if dialing from outside the U.S.). The conference ID is 28969045.
Within 24 hours of the webcast, a replay will be available under the "Events & Presentations" section of the Investor Relations portion of the Cyberonics website, where it will be archived and accessible for approximately 12 months.
About Cyberonics, Inc. and the VNS Therapy System
Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.
Safe harbor statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words. Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning introducing a new tablet-based programming device, filing regulatory submissions in Europe for the AspireSR, and the ProGuardian product by the end of fiscal 2014, as well as advancing the Relay generator, and obtaining a review of CMS's 2007 Non-Coverage Determination, obtaining reimbursement for the treatment-resistant depression indication, and financial guidance for fiscal 2014. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our products; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of new products, including VNS Therapy for the treatment of other indications; satisfactory completion of the post-market registry required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new products and indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 27, 2012, our Quarterly Report on Form 10-Q for the fiscal quarter ended July 27, 2012, our Quarterly Report on Form 10Q for the fiscal quarter ended October 26, 2012, and our Quarterly Report on Form 10Q for the fiscal quarter ended January 25, 2013.
Contact information
Greg Browne, CFOCyberonics, Inc.100 Cyberonics Blvd.Houston, TX 77058Main: (281) 228-7262Fax: (281) 218-9332ir@cyberonics.com
| NAME | LAST | CHNG | % CHNG | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # | CYBX | 51.49 | +1.32 | +2.63 | ||||||||||||
| # | EPS | 56.60 | +0.16 | +0.29 | ||||||||||||
CYBERONICS, INC. AND SUBSIDIARY
| ||||||||||||||||
CONSOLIDATED STATEMENTS OF INCOME
| ||||||||||||||||
(Unaudited except where indicated)
| ||||||||||||||||
For the Thirteen Weeks Ended
|
For the Fifty-Two Weeks Ended
| |||||||||||||||
April 26, 2013
|
April 27, 2012
|
April 26, 2013
|
April 27, 2012
| |||||||||||||
(Audited)
| ||||||||||||||||
Net sales
|
$
|
68,343,567
|
$
|
57,609,009
|
$
|
254,320,417
|
$
|
218,502,731
| ||||||||
Cost of sales
|
6,359,064
|
4,474,145
|
21,907,264
|
19,656,332
| ||||||||||||
Gross profit
|
61,984,503
|
53,134,864
|
232,413,153
|
198,846,399
| ||||||||||||
Operating expenses:
| ||||||||||||||||
Selling, general and administrative
|
29,975,531
|
26,038,981
|
112,515,262
|
102,568,776
| ||||||||||||
Research and development
|
11,545,403
|
9,128,198
|
41,551,444
|
35,334,770
| ||||||||||||
Total operating expenses
|
41,520,934
|
35,167,179
|
154,066,706
|
137,903,546
| ||||||||||||
Income from operations
|
20,463,569
|
17,967,685
|
78,346,447
|
60,942,853
| ||||||||||||
Interest income
|
43,653
|
81,675
|
84,287
|
326,118
| ||||||||||||
Interest expense
|
(18,260)
|
(46,428)
|
(119,303)
|
(296,725)
| ||||||||||||
Other expense net
|
(129,342)
|
(69,089)
|
(3,036,806)
|
(550,818)
| ||||||||||||
Income before income taxes
|
20,359,620
|
17,933,843
|
75,274,625
|
60,421,428
| ||||||||||||
Income tax expense
|
8,827,549
|
7,270,623
|
28,917,123
|
24,343,696
| ||||||||||||
Net income
|
$
|
11,532,071
|
$
|
10,663,220
|
$
|
46,357,502
|
$
|
36,077,732
| ||||||||
Basic income per share
|
$
|
0.42
|
$
|
0.39
|
$
|
1.68
|
$
|
1.30
| ||||||||
Diluted income per share
|
$
|
0.41
|
$
|
0.38
|
$
|
1.66
|
$
|
1.28
| ||||||||
Shares used in computing basic income per share
|
27,564,780
|
27,570,002
|
27,604,006
|
27,826,586
| ||||||||||||
Shares used in computing diluted income per share
|
27,910,627
|
28,055,627
|
28,008,960
|
28,306,732
| ||||||||||||
CYBERONICS, INC. AND SUBSIDIARY
| ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS
| ||||||||
(Unaudited except where indicated)
| ||||||||
April 26, 2013
|
April 27, 2012
| |||||||
(Audited)
| ||||||||
ASSETS
| ||||||||
Current Assets
| ||||||||
Cash and cash equivalents
|
$
|
120,708,572
|
$
|
96,654,275
| ||||
Short-term investments and restricted cash
|
15,099,573
|
—
| ||||||
Accounts receivable, net
|
39,450,113
|
29,266,847
| ||||||
Inventories
|
17,718,454
|
14,385,875
| ||||||
Deferred tax assets
|
10,297,991
|
16,994,209
| ||||||
Other current assets
|
4,083,640
|
3,801,705
| ||||||
Total Current Assets
|
207,358,343
|
161,102,911
| ||||||
Property, plant and equipment, net
|
28,555,742
|
22,160,671
| ||||||
Intangible assets, net
|
9,219,999
|
4,509,612
| ||||||
Long-term investments
|
10,588,202
|
9,508,768
| ||||||
Deferred tax assets
|
7,825,286
|
14,265,574
| ||||||
Other assets
|
495,738
|
360,659
| ||||||
Total Assets
|
$
|
264,043,310
|
$
|
211,908,195
| ||||
LIABILITIES AND STOCKHOLDERS' EQUITY
| ||||||||
Current Liabilities
| ||||||||
Accounts payables and accrued liabilities
|
$
|
29,025,478
|
$
|
23,032,636
| ||||
Convertible notes
|
—
|
4,000
| ||||||
Total Current Liabilities
|
29,025,478
|
23,036,636
| ||||||
Long-term Liabilities
|
5,449,604
|
5,402,189
| ||||||
Total Liabilities
|
34,475,082
|
28,438,825
| ||||||
Total Stockholders' Equity
|
229,568,228
|
183,469,370
| ||||||
Total Liabilities and Stockholders' Equity
|
$
|
264,043,310
|
$
|
211,908,195
| ||||
CYBERONICS, INC. AND SUBSIDIARY
| ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| ||||||||
(Unaudited except where indicated)
| ||||||||
For the Fifty-Two Weeks Ended
| ||||||||
April 26, 2013
|
April 27, 2012
| |||||||
(Audited)
| ||||||||
Cash Flow From Operating Activities:
| ||||||||
Net income
|
$
|
46,357,502
|
$
|
36,077,732
| ||||
Non-cash items included in net income:
| ||||||||
Depreciation
|
3,770,756
|
3,474,612
| ||||||
Amortization
|
867,613
|
1,228,245
| ||||||
Stock-based compensation
|
11,683,249
|
11,102,237
| ||||||
Deferred income taxes
|
22,421,044
|
22,666,255
| ||||||
Deferred license revenue amortization
|
(1,493,968)
|
(1,493,968)
| ||||||
Impairment of investment
|
4,058,768
|
—
| ||||||
Gain on warrants' liability
|
(1,325,574)
|
—
| ||||||
Unrealized loss in foreign currency transactions and other
|
136,344
|
1,808,435
| ||||||
Changes in operating assets and liabilities:
| ||||||||
Accounts receivable, net
|
(10,184,633)
|
(1,247,219)
| ||||||
Inventories
|
(3,395,899)
|
682,445
| ||||||
Other current assets
|
(304,992)
|
(451,694)
| ||||||
Other assets
|
(100,080)
|
51,748
| ||||||
Accounts payable and accrued liabilities
|
6,563,629
|
1,127,337
| ||||||
Net cash provided by operating activities
|
79,053,759
|
75,026,165
| ||||||
Cash Flow From Investing Activities:
| ||||||||
Short-term investments and restricted cash
|
(15,099,573)
|
—
| ||||||
Investment in convertible preferred stock
|
(6,588,201)
|
(4,000,000)
| ||||||
Intangible asset purchases
|
(4,600,000)
|
(500,000)
| ||||||
Purchases of property, plant and equipment
|
(9,705,446)
|
(17,484,102)
| ||||||
Net cash used in investing activities
|
(35,993,220)
|
(21,984,102)
| ||||||
Cash Flow From Financing Activities:
| ||||||||
Proceeds from exercise of options for common stock
|
9,742,948
|
10,772,767
| ||||||
Purchase of treasury stock
|
(33,009,394)
|
(50,444,649)
| ||||||
Repurchase of convertible notes
|
—
|
(7,044,000)
| ||||||
Realized excess tax benefits – stock compensation based
|
4,416,583
|
—
| ||||||
Net cash used in financing activities
|
(18,849,863)
|
(46,715,882)
| ||||||
Effect of exchange rate changes on cash and cash equivalents
|
(156,379)
|
1,014,244
| ||||||
Net increase in cash and cash equivalents
|
24,054,297
|
7,340,425
| ||||||
Cash and cash equivalents at beginning of period
|
96,654,275
|
89,313,850
| ||||||
Cash and cash equivalents at end of period
|
$
|
120,708,572
|
$
|
96,654,275
| ||||
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
| |||||||
(Unaudited)
| |||||||
The following tables set forth the reconciliation between U.S. GAAP and our non-GAAP financial measures for income from operations, net income and diluted income per share (unaudited):
| |||||||
Thirteen Weeks Ended
| |||||||
April 26, 2013
|
April 27, 2012
| ||||||
Net income
|
$
|
11,532,071
|
$
|
10,663,220
| |||
Tax adjustment relating to impairment of investment
|
1,339,561
|
—
| |||||
Adjusted non-GAAP net income
|
$
|
12,871,632
|
$
|
10,663,220
| |||
Diluted income per share
|
$
|
0.41
|
$
|
0.38
| |||
Per share effect of tax adjustment on impairment
|
0.05
|
—
| |||||
Adjusted non-GAAP diluted income per share
|
$
|
0.46
|
$
|
0.38
| |||
Fifty-Two Weeks Ended
| |||||||
April 26, 2013
|
April 27, 2012
| ||||||
Income from operations
|
$
|
78,346,447
|
$
|
60,942,853
| |||
Product withdrawal (1)
|
—
|
1,276,451
| |||||
Impairment of intangibles
|
—
|
482,603
| |||||
Adjusted non-GAAP income from operations
|
$
|
78,346,447
|
$
|
62,701,907
| |||
Fifty-Two Weeks Ended
| |||||||
April 26, 2013
|
April 27, 2012
| ||||||
Net income
|
$
|
46,357,502
|
$
|
36,077,732
| |||
Product withdrawal (1)
|
—
|
792,804
| |||||
Impairment of intangibles
|
—
|
331,881
| |||||
Impairment of investment (2)
|
3,812,162
|
—
| |||||
Gain on warrants liability
|
(1,325,574)
|
—
| |||||
Adjusted non-GAAP net income
|
$
|
48,844,090
|
$
|
37,202,417
| |||
Diluted income per share
|
$
|
1.66
|
$
|
1.28
| |||
Per share effect of product withdrawal
|
—
|
0.03
| |||||
Per share effect of impairment of intangibles
|
—
|
0.01
| |||||
Per share effect of impairment of investment
|
0.13
|
—
| |||||
Per share effect of gain on warrant liability
|
(0.05)
|
—
| |||||
Adjusted non-GAAP diluted income per share
|
$
|
1.74
|
$
|
1.32
| |||
(1)
|
The effect of AspireHC and AspireSR product withdrawals, gross and net of tax
|
(2)
|
The impairment relates to our investment in the convertible debt instrument of NeuroVista.
|
The following table sets forth the reconciliation between adjusted non-GAAP net income and our non-GAAP financial measure for adjusted EBITDA (unaudited):
| ||||||||
Thirteen Weeks Ended
| ||||||||
April 26, 2013
|
April 27, 2012
| |||||||
Adjusted non-GAAP net income
|
$
|
12,871,632
|
$
|
10,663,220
| ||||
Interest expense, net
|
(25,394)
|
(35,247)
| ||||||
Other expense, net
|
129,343
|
69,088
| ||||||
Income tax expense (1)
|
7,487,988
|
7,270,623
| ||||||
Depreciation and amortization
|
1,197,355
|
1,130,874
| ||||||
Equity based compensation
|
2,573,827
|
2,671,298
| ||||||
Adjusted EBITDA
|
$
|
24,234,751
|
$
|
21,769,856
| ||||
Fifty-Two Weeks Ended
| ||||||||
April 26, 2013
|
April 27, 2012
| |||||||
Adjusted non-GAAP net income
|
$
|
48,844,090
|
$
|
37,202,417
| ||||
Interest expense, net
|
35,015
|
(29,393)
| ||||||
Other expense, net
|
303,612
|
547,148
| ||||||
Income tax expense(1)
|
29,163,729
|
24,978,065
| ||||||
Depreciation and amortization
|
4,638,369
|
4,220,254
| ||||||
Stock based compensation
|
11,683,249
|
11,102,237
| ||||||
Adjusted EBITDA
|
$
|
94,668,064
|
$
|
78,020,728
| ||||
(1)
|
Income tax expense has been adjusted for non-GAAP items
|
No comments:
Post a Comment